Free Trial

Monopar Therapeutics (MNPR) Competitors

Monopar Therapeutics logo
$46.82 -0.05 (-0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$46.80 -0.02 (-0.05%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MNPR vs. ELVN, GPCR, BGM, PRAX, ARDX, AVDL, SANA, DYN, AKBA, and COLL

Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), BGM Group (BGM), Praxis Precision Medicines (PRAX), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Akebia Therapeutics (AKBA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

Monopar Therapeutics vs. Its Competitors

Enliven Therapeutics (NASDAQ:ELVN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Enliven Therapeutics presently has a consensus target price of $41.20, indicating a potential upside of 87.70%. Monopar Therapeutics has a consensus target price of $60.00, indicating a potential upside of 28.15%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Monopar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.43
Monopar TherapeuticsN/AN/A-$15.59M-$3.48-13.45

Enliven Therapeutics' return on equity of -31.84% beat Monopar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -31.84% -30.09%
Monopar Therapeutics N/A -55.39%-51.53%

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enliven Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

In the previous week, Enliven Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.44 beat Enliven Therapeutics' score of 0.40 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Monopar Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Enliven Therapeutics beats Monopar Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNPR vs. The Competition

MetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$286.54M$3.06B$5.67B$9.50B
Dividend YieldN/A2.44%4.05%4.00%
P/E Ratio-13.4520.9027.9219.98
Price / SalesN/A245.97397.1882.73
Price / CashN/A41.9636.1958.45
Price / Book5.198.288.635.82
Net Income-$15.59M-$55.19M$3.24B$258.42M
7 Day Performance-0.91%5.09%3.17%1.94%
1 Month Performance40.60%17.64%10.73%12.08%
1 Year Performance1,363.13%7.03%35.04%20.90%

Monopar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNPR
Monopar Therapeutics
2.7912 of 5 stars
$46.82
-0.1%
$60.00
+28.2%
+1,364.7%$286.54MN/A-13.4510Positive News
ELVN
Enliven Therapeutics
2.7025 of 5 stars
$21.87
-3.5%
$41.20
+88.4%
-9.1%$1.11BN/A-11.3950Insider Trade
GPCR
Structure Therapeutics
3.0105 of 5 stars
$18.13
-5.8%
$76.17
+320.1%
-49.5%$1.10BN/A-20.84136Positive News
BGM
BGM Group
N/A$10.63
-5.8%
N/AN/A$1.10B$25.10M0.00298News Coverage
Gap Up
High Trading Volume
PRAX
Praxis Precision Medicines
2.6076 of 5 stars
$55.16
+2.4%
$94.11
+70.6%
-1.9%$1.10B$8.55M-5.15110
ARDX
Ardelyx
4.0054 of 5 stars
$4.42
+0.2%
$10.89
+146.4%
-22.8%$1.06B$361.71M-20.0990
AVDL
Avadel Pharmaceuticals
2.0489 of 5 stars
$10.98
+1.4%
$18.33
+67.0%
-31.9%$1.05B$169.12M-40.6770
SANA
Sana Biotechnology
3.2111 of 5 stars
$4.44
-4.1%
$9.17
+106.5%
-18.3%$1.04BN/A-5.05380Gap Up
DYN
Dyne Therapeutics
3.7843 of 5 stars
$9.17
+1.7%
$40.63
+343.0%
-78.7%$1.03BN/A-2.55100
AKBA
Akebia Therapeutics
3.8352 of 5 stars
$3.84
-0.5%
$6.75
+75.8%
+174.7%$1.01B$184.91M-18.28430Positive News
COLL
Collegium Pharmaceutical
4.4826 of 5 stars
$30.91
-0.9%
$43.75
+41.5%
-3.6%$1.00B$631.45M25.34210News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:MNPR) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners